PMID- 28540228
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 6
IP  - 2
DP  - 2017 Apr
TI  - Research in pharmacotherapy for erectile dysfunction.
PG  - 207-215
LID - 10.21037/tau.2016.11.17 [doi]
AB  - Although oral phosphodiesterase-5 (PDE5) inhibitors are generally accepted as an 
      effective therapy for erectile dysfunction (ED), men with ED from diabetes or 
      radical prostatectomy respond poorly to these drugs. Many researchers have tried 
      to develop novel therapeutics that target alternative molecular pathways. A group 
      of therapeutics belongs to centrally acting agents that target dopamine and 
      melanocortin receptors. The other one is the peripherally acting agents that 
      target soluble guanylate cyclase, Rho-kinase pathway, and Maxi-K channel, etc. 
      Also, a variety of preclinical studies by the application of biotherapies in the 
      concept of therapeutic angiogenesis or neural regeneration as well as 
      anti-fibrosis to regenerate damaged erectile tissue have been reported. This 
      article will address the current therapeutic targets for ED under clinical or 
      preclinical development, including pharmacotherapy and biotherapy which comprises 
      protein therapy and gene therapy. In spite of numerous clinical trials that 
      target alternative pathways, these agents have yet to reach the market. The 
      results from preclinical studies targeting therapeutic angiogenesis, neural 
      regeneration, and anti-fibrosis are promising.
FAU - Ryu, Ji-Kan
AU  - Ryu JK
AD  - National Research Center for Sexual Medicine and Department of Urology, Inha 
      University School of Medicine, Incheon 400-711, Korea.
FAU - Suh, Jun-Kyu
AU  - Suh JK
AD  - National Research Center for Sexual Medicine and Department of Urology, Inha 
      University School of Medicine, Incheon 400-711, Korea.
FAU - Burnett, Arthur L
AU  - Burnett AL
AD  - Department of Urology, The James Buchanan Brady Urological Institute, Johns 
      Hopkins Medical Institutions, Baltimore, MD 21287, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC5422707
OTO - NOTNLM
OT  - Erectile dysfunction (ED)
OT  - clinical trial
OT  - pharmacotherapy
OT  - preclinical studies
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2017/05/26 06:00
MHDA- 2017/05/26 06:01
PMCR- 2017/04/01
CRDT- 2017/05/26 06:00
PHST- 2017/05/26 06:00 [entrez]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2017/05/26 06:01 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - tau-06-02-207 [pii]
AID - 10.21037/tau.2016.11.17 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2017 Apr;6(2):207-215. doi: 10.21037/tau.2016.11.17.